Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235—a dual PI3K/mTOR inhibitor—and RAD001—an mTOR inhibitor—in 13 en...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Keiko, Oda, Katsutoshi, Kashiyama, Tomoko, Ikeda, Yuji, Nakagawa, Shunsuke, Sone, Kenbun, Miyamoto, Yuichiro, Hiraike, Haruko, Tanikawa, Michihiro, Miyasaka, Aki, Koso, Takahiro, Matsumoto, Yoko, Wada-Hiraike, Osamu, Kawana, Kei, Kuramoto, Hiroyuki, McCormick, Frank, Aburatani, Hiroyuki, Yano, Tetsu, Kozuma, Shiro, Taketani, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360787/
https://www.ncbi.nlm.nih.gov/pubmed/22662154
http://dx.doi.org/10.1371/journal.pone.0037431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360787/
https://www.ncbi.nlm.nih.gov/pubmed/22662154
http://dx.doi.org/10.1371/journal.pone.0037431

Ejemplares similares